

Ajanta House, Charkop Kandivli (West), Mumbai - 400 067 India

T +91 22 6606 1000
F +91 22 6606 1200
E legal.info@ajantapharma.com
W www.ajantapharma.com



16th July 2024

BSE LIMITED
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400001

National Stock Exchange of India, Exchange Plaza, 5th Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051

Scrip Code: BSE – AJANTPHARM 532331

Scrip Code: NSE AJANTPHARM EQ

Re: Compliance with Reg. 27(2) of the Listing Regulations - Report on Corporate Governance

Dear Sir/Madam,

Pursuant to Regulation 27(2) of the Listing Regulation, enclosed please find Compliance Report on Corporate Governance for the quarter ended on 30th June 2024.

Thanking You,

Yours faithfully,

GAURANG SHAH

Sr. VP - Legal & Company Secretary

Encl.: a/a

For Format of report on Corporate Governance to be submitted by listed entity on quarterly basis

Name of Listed Entity
 Quarter ending

: Ajanta Pharma Limited : 30th June 2024

Titl	Mame of the		Category	Initial Date	Date of Re-	Date	Tenure	Date of	No of	No of	Number of	No of
e (Mr. / Ms.)	Director	& DIN	(Chairperson /Executive/ Non- Executive/ independent/ Nominee) ^{&}	of Appointmen t	appointment	of Cess ation	*	Birth	Direct orship in listed entiti es includ	Indepen dent Director ship in listed entities includin	Number of memberships in Audit/Stakeholder Committee(s) including this listed entity (Refer	No of pos of Chairperson in Audit Stakeholder Committee
									ing this listed entity (in refer ence to Regul ation 17A (1)	g this listed entity [in reference to proviso to regulation 17A (1)]	Regulation 26(1) of Listing Regulations)	held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulation s)
Mr.	Mannalal B. Agrawal	AACPA2742D & 00073828	Chairperson & Non-Executive Director	31.12.1979	04.08.2022 #	-	-	26.03.1947	1	0	Audit - 1 SRC - 1	Of 1 SRC Committee
Mr.	Madhusudan B. Agrawal	AAHPA8178J & 00073872	Executive Director	31.12.1979	01.04.2020	-	-	29.03.1955	1	0	None	None
Mr.	Yogesh M. Agrawal	AACPA2793C & 00073673	Executive Director	29.04.2000	01.04.2023	-	-	14.01.1972	1	0	None	None
Mr.	Rajesh M. Agrawal	AACPA2792D & 00302467	Executive Director	30.04.2013	01.05.2023	-		31.03.1976	2	1	Audit - 0 SRC - 1	None
Mr.	Chandrakant Khetan	AAHPK5606M & 00234118	Independent Director	20.10.2008	18.07.2019	-	115.27 months	24.01.1946	1	1	None	None

Mr.	KH	ALJPK1873B	Independent	30.04.2013	18.07.2019	T	445.55					
	Viswanathan	& 06563472	Director	30.01.2013	18.07.2019	-	115.27 months	11.01.1946	1	1	None	None
Mr.	Prabhakar Dalal	ADKPD7258G & 00544948	Independent Director	13.06.2014	18.07.2019	-	115.27 months	09.01.1953	4	4	Audit - 3	J. Z AC a
Dr.	Anjana	AFNPG6211K	Indonesident	42.04.004							SRC - 1	SRC
	Grewal	& 06896404	Independent Director	13.06.2014	18.07.2019	-	115.27 months	01.11.1953	1	1	None	None
Mr.	David	AAGPR6480F	Independent	02.05.2024			0.57	01.01.10				
	Rasquinha	& 01172654	Director	02.05.2024			0.57	01.06.1961	2	2	Audit -1	Of 1 AC Committee
Ms.	Medha Joshi	AAFPJ7133C	Independent				months					
		& 00328174	Director			-	0.57	24.06.1956	1	1	None	None
Mr.	Rajesh Dalal	AARPD5462C	Independent	02.05.2024		-	months	12 22 1272				
		& 03504969	Director			-	0.57	12.09.1953	2	2	Audit - 2	Of 1 SRC
Ms.	Simi Thapar	ABWPT7148	Independent	02.05.2024			months				SRC - 1	Committee
		M & 10470498	Director	1			0.57 months	20.08.1969	1	1	Audit - 1 SRC - 1	None
Whetl	her regular Chai	irperson appoin	ted: Yes									
Whetl	her Chairperson	is related to m	anaging director	or CFO: Voc							i Financia	
# Re-a	appointed pursu	ant to retireme	ent by rotation	or cho. Tes								
Wheth	her Chairperson appointed pursu	is related to m	anaging director	or CEO: Yes								

Name of Committee	Whether Regular chairperson appointed	Name of Committee members	Category (Chairperson/Executive/Non-Executive/Independent/Nominee) \$	Date of Appointment	Date of Cessation
1. Audit Committee	Yes	Mr. David Rasquinha Mr. Mannalal B. Agrawal Mr. Rajesh Dalal Ms. Simi Thapar	Independent Director, Member of Committee	02-05-2024 15-07-2000 02-05-2024	
2. Nomination & Remuneration Committee	Yes	Mr. Rajesh Dalal Mr. David Rasquinha Ms. Medha Joshi	Independent Director, Member of Committee Independent Director, Chairman of Committee Independent Director, Member of Committee Independent Director, Member of Committee	02-05-2024 02-05-2024 02-05-2024	
3. Risk Management Committee	Yes	Mr. Yogesh M. Agrawal Mr. Rajesh M. Agrawal Mr. Rajesh Dalal Mr. Arvind K. Agrawal	Managing Director, Chairman of Committee Joint Managing Director, Member of Committee Independent Director, Member of Committee Chief Financial Officer, Member of Committee	02-05-2024 09-08-2017 09-08-2017 02-05-2024	
4. Stakeholders Relationship Committee		Mr. Mannalal B. Agrawal Mr. Rajesh M. Agrawal	Non-Executive Chairperson of Company, Chairman of Committee Executive Director, Member of Committee Independent Director, Member of Committee	09-08-2017 30-04-2019 29-07-2013 02-05-2024	

III. Meeting of Board of					
Date(s) of Meeting (if any) in the previous quarter	Date(s) of Meeting (if any) in the relevant quarter	Whether requirement of Quorum met*			Maximum gap between any two consecutive (in number of days)
31 st January 2024 5 th March 2024	2 nd May 2024	Yes	8	4	57 days
* to be filled in only for	the current quarter meetin	gs			

ate(s) of meeting of the ommittee in the relevant uarter		Number of Directors present *	Number of Independent directors' present *		Maximum gap between any two consecutive meetings in number of days*
nd May 2024 This information has to be m	Yes	4	3	31st January 2024	91 days

V. Related Party Transactions	
Subject	Compliance status (Yes/No/NA) refer note below
Whether prior approval of audit committee obtained	Yes
	Material RPTs are only with Wholly Owned subsidiary of the Company and shareholder's approval is not required for such RPTs as per Regulation 23(5) of the Listing Regulations.
Whether details of RPT entered into pursuant to omnibus	Yes Yes
approval have been reviewed by Audit Committee	
Note:	

1. In the column "Compliance Status", compliance or non-compliance may be indicated by Yes/No/N.A. For example, if the Board has been composed in accordance with the requirements of Listing Regulations, "Yes" may be indicated. Similarly, in case the Listed Entity has no related party transactions, the words "N.A." may be indicated.

2. If status is "No" details of non-compliance may be given here.



VI. Affirmations

- 1. The composition of Board of Directors is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 2. The composition of the following committees is in terms of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
 - a. Audit Committee
 - b. Nomination & Remuneration committee
 - c. Stakeholders relationship committee
 - d. Risk management committee (applicable to the top 1000 listed entities): Applicable
- 3. The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 4. The meetings of the Board of Directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.
- 5. This report will be placed before Board of Directors at the ensuing Board meeting.

Name & Designation: Gaurang Shah

Company Secretary / Compliance Officer / Managing Director / CEO / CFO: Company Secretary & Compliance Officer

